By Adib Motiwala of http://adibmotiwala.blogspot.com/
This summer I have taken a Private Equity course at the University of Texas at Dallas as part of my MBA coursework. In this course, the instructor employs case based discussions along with industry speakers.
In the first few cases, we focussed on Levered Buy Outs (LBO). It was interesting to learn that private equity investors also focussed on cash flows just as a public equity investor should. The measure often used by private equity investors is EBITDA or Earnings Before Interest Taxes Depreciation and Amortization. Now, EBITDA is not the same as cash from operations however it is often used as a quick shortcut.
Voss Value Is Betting On The American Consumer Recovery: Q4 Letter
In Q4 2020, the Voss Value Fund, LP and the Voss Value Offshore Fund, Ltd., returned 20.8% and 20.7% to investors net of fees and expenses, respectively, compared to a 31.4% total return for the Russell 2000, a 32.7% total return for the Russell 2000 Value, and a 12.2% total return for the S&P 500. Read More
One of the reasons for using EBITDA rather than EBIT or Net Income is that when you compare companies across the world which have different capital structures as well as different tax rates and depreciation schedules, it makes sense to adjust for all these differences. EBITDA is an easy way to adjust for this and compare such companies. In the podcast by theValueGuys, Val also often refers to the EV/EBITDA as a form of valuation.
I found that Tom Russo also uses EBITDA as a measure when looking at investment candidates. Here is an exercept from his talk at the Value Investor Congress found on GuruFocus.com
In 1989 (I started investigating foreign companies in ’87) this is where it starts. Weetabix’s EBITDA was 19 million pounds and it had 7 million pounds of cash. I determined the business was worth 8 times EBITDA plus cash, less debt, and I came up with an intrinsic value of 13 pounds. With 11.87 million shares outstanding it was trading at 5.95 pounds per share. Then each pound was worth US$1.61 So that’s the beginning of the story. Now, I would mention that I used the word EBITDA, which Buffett this weekend suggested was false signs and all sorts of horrors would ensue if you even mentioned those six letters in rough approximation to each other. But for me at least, EBITDA is useful because it helps me cross countries because of different depreciation schedules and amortization schedules.
It’s one thing to say in a U.S. context that you’ve looked at pre-tax earnings rather than EBITDA. But when you start to look at Heineken versus Cadbury Schweppes versus Budweiser, and if you don’t adjust for those non-cash charges — and one way to do it is using EBITDA — you have a more difficult time comparing across the market. I have used EBITDA, and I confess it in front of you.
In “The Little Book of Value Investing”, Chris Browne stated that other than the P/E and P/B multiples, he would also look at what a private equity investor would pay for a company. He called it the ‘appraisal method’. I am not totally sure but he could probably be referring to the EV/EBITDA multiple.
Of course, no one measure or valuation method should be used by itself. However, EBITDA is another tool that an investor should have in his toolbox.
Let us look at some fashion retailers.
American Eagle (AEO) : 4.5
Abercombie & Fitch (ANF) : 5.9
Aeropostale (ARO) : 5.1
Hot Topic : 3
J Crew 6
Retailers throw out good cash flow most of the times, however they can be considered cyclical and often fall out of favor with their fashion fickle customers.
1) Capex: EBITDA does not take into account the capex required by a business (as compared to Free cash flow which is Cash from operations – Capex). An adjustment that one can make is to look at
EV / EBITDA – Capex.
After accounting for capex if the valuation is not as attractive, then you can pass it over.
Example: Consider Tenet Healthcare (THC)
EV : $5.85 billion
EBITDA: $1 billion
You will see it trades at a somewhat attractive 5.84x EBITDA. However, if you subtract capex of $456 million from EBITDA, you will arrive at this adjusted measure of 10.74x. Clearly, not as attractive as originally thought.
2) Interest coverage/ high leverage: EBITDA also ignores the interest payment required and the existing level of leverage in the company. I would advocate looking at two additional measures.
(i) Interest coverage as indicated by EBIT/ Interest expense. A low interest coverage should be a red flag.
Coming back to our THC example, interest coverage = 1.46. A very low number.
(ii) LT Debt / EBITDA or Debt / Equity: Graham advised against investment in a company where Debt is 2x equity.
If you look at THC, LT Debt = $4.27 billion and equity = $646 million.
So, LT Debt / EBITDA = 4.27x and Debt / Equity = 6.6x.